Subscribe To
TBPH / Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return
TBPH News
By Seeking Alpha
September 9, 2023
Theravance: Positive Findings Boost Ampreloxetine Development
Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's fina more_horizontal
By Seeking Alpha
September 8, 2023
Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold
Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation fo more_horizontal
By PRNewsWire
August 28, 2023
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new amprel more_horizontal
By Zacks Investment Research
August 8, 2023
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year. more_horizontal
By Seeking Alpha
August 7, 2023
Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Exec more_horizontal
By Zacks Investment Research
August 7, 2023
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to more_horizontal
By Seeking Alpha
May 3, 2023
Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return
Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initi more_horizontal
By PRNewsWire
April 10, 2023
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conferenc more_horizontal